Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance

摘要

A compound which binds to a receptor for glucagon-like peptide-1 is used in the manufacture of a medicament for treating impaired glucose tolerance in an individual who has not been diagnosed with non-insulin dependent diabetes mellitus or for decreasing the risk of a cardiovascular event or cerebrovascular event associated with IGT. Preferably the compound is a GLP-1 (7-37) having the sequence His-Ala-Glu-GLy-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly (SE ID NO:3), exendin 3 or exedin 4. (62) Divided out of 508823